hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337214, orgStudyIdInfo id: TCHIRB-11301014-E, briefTitle: TCM Therapy Program Impact on Breast Cancer Patients' Vital Energy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Taipei City Hospital, class: OTHER_GOV, descriptionModule briefSummary: The goal of this study is to evaluate the impact of the "Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy" on patients with breast cancer who are currently undergoing conventional Western medical treatments in Taiwan. The main questions it aims to answer are:Can the "Traditional Chinese Medicine Therapy Program" alleviate symptoms experienced by breast cancer patients? Does the program improve the quality of life for breast cancer patients receiving Western medical treatments? How does the program contribute to the management of side effects associated with Western oncological therapies?Participants will:Engage in the "Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy" provided by the Taiwan Compassionate Cancer Care Association.Receive supportive and educational services, including auxiliary Chinese medicine treatment courses, lifestyle and health education, and psychological counseling.This study seeks to integrate the concept of holistic healthcare, emphasizing coordinated care that encompasses physical, mental, and social aspects, into the treatment of breast cancer., conditionsModule conditions: Breast Cancer, conditions: Neoplasm, Breast, conditions: Patient Participation, conditions: Mental Health Issue, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Traditional Chinese Medicine Therapy Program for Reinforcing Vital Energy, outcomesModule primaryOutcomes measure: Questionnaire: Constitution in Chinese Medicine Questionnaire, primaryOutcomes measure: Questionnaire: Functional Assessment of Cancer Therapy-General Scale, FACT-G)(Version 4), primaryOutcomes measure: Questionnaire: European Organisation for Research and Treatment of Cancer, EORTC QLQ-BR23), secondaryOutcomes measure: Additional questions regarding the "Traditional Chinese Medicine Program for Reinforcing Vital Energy", eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Taipei City Hospital, status: RECRUITING, city: Taipei, zip: 10845, country: Taiwan, contacts name: Yu-Hsuan Tai, MD, role: CONTACT, phone: +886918130891, email: daidayangisele@gmail.com,dbb02@tpech.gov.tw, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06337188, orgStudyIdInfo id: AAC PhII, briefTitle: Adaptive and Individualized AAC Phase II, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Altec Inc., class: INDUSTRY, collaborators name: University of Nebraska, descriptionModule briefSummary: The overall objective of this study is to develop an Augmentative and Alternative Communication (AAC) system that is effective in delivering a person-centric communication device that will provide a versatile access method that can automatically learn and adapt to the user's physical abilities by creating a personalized, comprehensive keyboard interface for communication, not otherwise available to people in need of alternative communication., conditionsModule conditions: Communication Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Experimental AAC, interventions name: Generic AAC, outcomesModule primaryOutcomes measure: Tele-healthcare Satisfaction Questionnaire - Wearable Technology (TSQ-WT), primaryOutcomes measure: Information Transfer Rate, primaryOutcomes measure: National Aeronautics and Space Administration (NASA) Task Load Index, secondaryOutcomes measure: Character-to-character Movement Time, secondaryOutcomes measure: Path Efficiency, secondaryOutcomes measure: Frequency of Selecting Word Completion Options, secondaryOutcomes measure: Number of Written Disfluencies, eligibilityModule sex: ALL, minimumAge: 6 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337175, orgStudyIdInfo id: 000000230988, briefTitle: Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-06-01, primaryCompletionDateStruct date: 2023-10-30, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Kafrelsheikh University, class: OTHER, descriptionModule briefSummary: The investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for different subtypes of post-alteplase hemorrhagic transformation of brain infarction., conditionsModule conditions: Ischemic Stroke, conditions: Alteplase Adverse Reaction, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study consisted of two distinct groups. The first group comprised 464 patients who did not experience hemorrhagic infarction, while the second group comprised 152 patients who experienced hemorrhagic infarction., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Alteplase, interventions name: Alteplase, outcomesModule primaryOutcomes measure: predictors of the hemorrhagic infarction type 1, secondaryOutcomes measure: predictors of the hemorrhagic infarction type 2, secondaryOutcomes measure: predictors of the parenchymal hematoma type 1, secondaryOutcomes measure: predictors of the parenchymal hematoma type 2, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kafr Elsheikh University Hospital, status: RECRUITING, city: Kafr Ash Shaykh, zip: 33155, country: Egypt, contacts name: mohamed G. Zeinhom, MD, role: CONTACT, phone: 2001009606828, email: mohamed_gomaa@med.kfs.edu.eg, contacts name: sherihan R ahmed, MD, role: CONTACT, phone: 2001007481842, email: sherihanrezk2016@gmail.com, geoPoint lat: 31.11174, lon: 30.93991, hasResults: False
protocolSection identificationModule nctId: NCT06337162, orgStudyIdInfo id: UPCC 20223, secondaryIdInfos id: IRB#855195, type: OTHER, domain: University of Pennsylvania IRB, briefTitle: Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC), acronym: HCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-05-01, completionDateStruct date: 2028-09-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Abramson Cancer Center at Penn Medicine, class: OTHER, collaborators name: Incyte Corporation, descriptionModule briefSummary: This is a pilot safety study of the oral PD-L1 inhibitor INCB099280 in patients with HCC awaiting liver transplant., conditionsModule conditions: Hepatocellular Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: INCB099280, outcomesModule primaryOutcomes measure: Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy, secondaryOutcomes measure: Acute Cellular Rejection of Liver Transplant Within 3 Months, secondaryOutcomes measure: Acute Cellular Rejection of Liver Transplant Within 1 Year, secondaryOutcomes measure: Toxicity Rates by Category and Grade, secondaryOutcomes measure: Proportion of Patients Downstaged, secondaryOutcomes measure: Pathologic Complete Response Rate, secondaryOutcomes measure: Recurrence-Free Survival at 1 Year After Transplant, secondaryOutcomes measure: Overall Survival at 1 Year After Transplant, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Abramson Cancer Center at University of Pennsylvania, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, contacts name: Jennifer Walsh, role: CONTACT, phone: 215-615-5858, email: Jennifer.Walsh4@pennmedicine.upenn.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06337149, orgStudyIdInfo id: APHP230348, secondaryIdInfos id: IDRCB: 2023-A00006-39, type: REGISTRY, domain: IDRCB ANSM, briefTitle: Relationship Between Breathing and Attention in Children With Ondine Syndrome, acronym: OndineCo, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2026-09-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Congenital central hypoventilation syndrome (CCHS) is a rare disorder of autonomic and respiratory regulation that alters oxygen delivery to the brain. CCHS patients are at risk for broad neurocognitive deficits. Patients retain ventilatory activity when awake through a respiratory-related cortical network but the need to mobilise cortical resources to breathe lead to breathing-cognition interferences during cognitive tasks. The purpose of this study is to assess the relationship between breathing pattern and attention in CCHS children, conditionsModule conditions: Ondine Syndrome, conditions: Congenital Central Hypoventilation Syndrome (CCHS), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: neuropsychological tests used usually in clinical practice (TEA-ch, NEPSY, BRIEF) and research (Conners 3, K-CPT II or CPT III, Flankers Task), outcomesModule primaryOutcomes measure: Wechsler scale, primaryOutcomes measure: Nepsy II test, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Robert Debre Hospital, status: RECRUITING, city: Paris, zip: 75019, country: France, contacts name: Christophe DELCLAUX, MD, PhD, role: CONTACT, phone: +331 40 03 41 90, email: christophe.delclaux@aphp.fr, contacts name: Benjamin DUDOIGNON, MD, role: CONTACT, phone: +331 40 03 41 90, email: benjamin.dudoignon@aphp.fr, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06337136, orgStudyIdInfo id: 2022-A01837-36, briefTitle: neonAtal motoR paTtErn autoMatIc analySis, acronym: AIMOTHERNeo, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: This project consists in developing a computerized clinical assessment system for newborns that takes into account the four major criteria of the various clinical scales: facial mimicry, cry, posture and movement. Classification of motor patterns according to gestational age at birth The aim of this work is the automated identification of pathological motor patterns related to anoxo-ischemic encephalopathy/brachial plexus paralysis/early neonatal bacterial infection/stroke/etc ..., conditionsModule conditions: Automated Computer Analysis, conditions: Neonatal Motor Pattern, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, outcomesModule primaryOutcomes measure: comparison of the computer score with the clinical examination, secondaryOutcomes measure: Comparison of the evolution of neurological examination and posture based on the day of life for each patient and each group of patients, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 15 Days, stdAges: CHILD, contactsLocationsModule locations facility: Department of paediatric neurological care and intentive care unity (PICU), Raymond Poincaré hospital - APHP, city: Garches, zip: 92380, country: France, geoPoint lat: 48.84226, lon: 2.18232, hasResults: False
protocolSection identificationModule nctId: NCT06337110, orgStudyIdInfo id: 20436A, briefTitle: A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-05-25, completionDateStruct date: 2024-05-25, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: H. Lundbeck A/S, class: INDUSTRY, descriptionModule briefSummary: The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants., conditionsModule conditions: Healthy Participants, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 8, type: ESTIMATED, armsInterventionsModule interventions name: Lu AF28996, outcomesModule primaryOutcomes measure: Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces), primaryOutcomes measure: AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity, primaryOutcomes measure: Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material, primaryOutcomes measure: Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material, primaryOutcomes measure: T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material, primaryOutcomes measure: AUC0-infinity of Lu AF28996, primaryOutcomes measure: Cmax of Lu AF28996, primaryOutcomes measure: Tmax of Lu AF28996, primaryOutcomes measure: T½ of Lu AF28996, eligibilityModule sex: MALE, minimumAge: 35 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fortrea Clinical Research Unit Ltd, city: Holbeck, state: Leeds, zip: LS11 9EH, country: United Kingdom, geoPoint lat: 53.25, lon: -1.18333, hasResults: False
protocolSection identificationModule nctId: NCT06337097, orgStudyIdInfo id: 2023-1021, secondaryIdInfos id: NCI-2024-02687, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-02, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects., conditionsModule conditions: Immune Checkpoint Therapy, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 880, type: ESTIMATED, armsInterventionsModule interventions name: Troponin surveillance, interventions name: Standard of care, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, status: RECRUITING, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Nicolas Palaskas, MD, role: CONTACT, phone: 713-606-3957, email: nlpalaskas@mdanderson.org, contacts name: Nicolas Palaskas, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06337084, orgStudyIdInfo id: MNPR-101-D001, briefTitle: Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Monopar Therapeutics, class: INDUSTRY, descriptionModule briefSummary: The goal of this study is to test a new PET imaging agent in patients with solid tumors. This tracer is made of a radioactively-labeled monoclonal antibody MNPR-101, and can show where tumors are present in the body using a PET-scan. The investigators will investigate if the new imaging agent correctly shows all tumor lesions. In the future, this method may be useful to help predict who will benefit from certain therapies.Participants will be injected with the radioactive tracer once. After injection, participants will undergo 3 PET-scans. Each PET-scan will take a maximum of 30 minutes. The PET-scans are on separate days within 10 days after injection of the tracer (e.g., 2 hours after injection plus 3-5 days and 7-10 days after injection). Furthermore, the investigators will take blood samples 6 times (5 mL each). Blood pharmacokinetics (PK) will be measured on Day 1 at 10 min, 1h, 2h, once on Days 3-5, and once on Days 7-10.The amount of radioactivity injected will range between 37-74 MBq (±10%)., conditionsModule conditions: Solid Tumor, Adult, conditions: Bladder Cancer, conditions: Urothelial Carcinoma, conditions: Triple-negative Breast Cancer, conditions: Lung Cancer, conditions: Colorectal Cancer, conditions: Gastric Cancer, conditions: Ovarian Cancer, conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Diagnostic Test: MNPR-101-DFO*-89Zr PET Scan, outcomesModule primaryOutcomes measure: assess dosimetry and biodistribution of product, primaryOutcomes measure: assess tumor Standard Uptake Values (SUV) of product, secondaryOutcomes measure: assess pharmacokinetics (PK) levels of product, otherOutcomes measure: assess tumor uptake to background and tumor uptake to liver ratios of product, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Melbourne Theranostic Innovation Centre (MTIC), status: RECRUITING, city: North Melbourne, state: Victoria, zip: 3051, country: Australia, contacts name: Referral Coordinator, role: CONTACT, phone: 03 9454 5800, geoPoint lat: -37.80132, lon: 144.95822, hasResults: False
protocolSection identificationModule nctId: NCT06337071, orgStudyIdInfo id: AM2023MCV4Ⅱ, briefTitle: A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Aimei Vacin BioPharm (Zhejiang) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines. It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination; the 2-15 year-old group will have one dose vaccination., conditionsModule conditions: Meningococcal Meningitis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, interventions name: ACYW135 Meningococcal Polysaccharide Vaccine, outcomesModule primaryOutcomes measure: Immunogenicity 1, primaryOutcomes measure: Immunogenicity 2, primaryOutcomes measure: Immunogenicity 3, primaryOutcomes measure: Safety 1, secondaryOutcomes measure: Immunogenicity 4, secondaryOutcomes measure: Immunogenicity 5, secondaryOutcomes measure: Immunogenicity 6, secondaryOutcomes measure: Immunogenicity 7, secondaryOutcomes measure: Immunogenicity 8, secondaryOutcomes measure: Immune persistence 1, secondaryOutcomes measure: Immune persistence 2, secondaryOutcomes measure: Safety 2, secondaryOutcomes measure: Safety 3, secondaryOutcomes measure: Safety 4, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: Yunnan Center For Disease Control and Prevention, city: Kunming, state: Yunnan, zip: 650022, country: China, contacts name: ZHENG Yan, role: CONTACT, phone: +8687163627796, email: yaqueer_zy@163.com, geoPoint lat: 25.03889, lon: 102.71833, hasResults: False